Uncomplicated urinary tract infections. Antimicrobial susceptibility study in Navarre
DOI:
https://doi.org/10.23938/ASSN.0125Keywords:
Escherichia coli. Fosfomycin. Nitrofurantoin. Urinary tract infection. Resistance.Abstract
Background. Urinary tract infection (UTI) is a high prevalence infection at the community level. In order to improve the adequacy of the empirical therapy, we evaluated the etiology and the resistance pattern of the main uropathogens responsible for community acquired UTI in Navarre.
Methods. Retrospective study (1/01/2014-31/12/2016) in which we included microorganisms recovered with significant counts from samples of patients with community-acquired UTI. The global etiology and etiology according to age and sex was analyzed. Antimicrobial resistance was studied with uropathogens isolated in 2016.
Results. Escherichia coli was the most frequently isolated microorganism both in the population (60.8%) and in each of the groups analyzed according to age and sex. The sensitivity of E. coli was: nitrofurantoin 97.4%, fosfomycin 96.5% amoxicillin-clavulanic acid 3.8%, trimethoprim-sulfamethoxazole 68.3%. quinolones 63.4% and amoxicillin 41.9%. Pooled sensitivity shows that the sensitivity to fosfomycin was 83.4% in men <15 years, 89.4% in women <15 years and 81.9% in women between 15-65 years; and to nitrofurantoin was 86.7% in women <15 years and 82.2% in women between 15-65 years.
Conclusions. E. coli continues to be the most frequent microorganism in community-acquired UTI with a rate of sensitivity to fosfomycin and nitrofurantoin above 95%. The empirical treatment of UTI in our environment should not include amoxicillin, amoxicillin-clavulanic acid, trimethoprim-sulfamethoxazole or quinolones. Fosfomycin may be empirically used in the treatment of uncomplicated cystitis in men younger than 15 years and in women under 65 years, and nitrofurantoin may be used empirically in women under 65 years.
Downloads
References
MARTÍN SALAS C, GIL-SETAS A, MAZÓN A. Etiología y sensibilidad antibiótica de las infecciones extrahospitalarias más frecuentes. An Sist Sanit Navar 2006; 29: 27-36.
PITOUT JD, CHAN WW, CHURCH DL. Tackling antimicrobial resistance in lower urinary tract infections: treatment options. Expert Rev Anti Infect Ther 2016; 14: 621-632.
PALOU J, PIGRAU C, MOLINA I, LEDESMA JM, ANGULO J, GRUPO COLABORADOR ESPAÑOL DEL ESTUDIO ARESC. Etiology and sensitivity of uropathogens identified in uncomplicated lower urinary tract infections in women (ARESC Study): implications on empiric therapy. Med Clin (Barc) 2011; 136: 1-7.
SORLOZANO A, JIMENEZ-PACHECO A, DE DIOS LUNA DEL CASTILLO J, SAMPEDRO A, MARTINEZ-BROCAL A, MIRANDA-CASAS C et al. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: A 7-year surveillance study. Am J Infect Control 2014; 42: 1033-1038.
HORCAJADA JP, SORLI L, MONTERO M. Tratamiento de las infecciones no complicadas del tracto urinario inferior. Tratamiento de la pielonefritis aguda. En: Pigrau C, editor. Infección del tracto urinario. Madrid: Salvat, 2013; 57-72.
ANDREU DOMINGO A, CACHO J, COIRA NIETO A, LEPE JIMÉNEZ JA. Diagnóstico microbiológico de las infecciones del tracto urinario. Procedimientos en Microbiología Clínica. 2010.
https://www.seimc.org/contenidos/documentoscientificos/procedimientosmicrobiologia/seimc-procedimientomicrobiologia14a.pdf Consultado el 10 de noviembre de 2017
CLINICAL AND LABORATORY STANDARDS INSTITUTE. Performance standards for antimicrobial susceptibility testing; Twenty-fourth informational supplement (M100 S24). Wayne: Clinical and Laboratory Standards Institute; 2014.
TENA D, GONZÁLEZ-PRAETORIUS A, GONZÁLEZ JC, HEREDERO E, ILLESCAS S, DE BARANDA CS et al. Changes in the antimicrobial susceptibility of Escherichia coli isolates from community diagnosed urinary tract infections during the period 2003-2007. Multicentre study in Castilla la Mancha (Spain). Rev Esp Quimioter 2010; 23: 36-42.
GUPTA K, HOOTON TM, NABER KG, WULLT B, COLGAN R, MILLER LG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-120.
HOOTON TM, ROBERTS PL, COX ME, STAPLETON AE. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med. 2013; 369: 1883-1891.
ANDREU A, PLANELLS I. Etiology of community-acquired lower urinary infections and antimicrobial resistance of Escherichia coli: a national surveillance study. Med Clin (Barc) 2008; 130: 481-486.
FASUGBA O, MITCHELL BG, MNATZAGANIAN G, DAS A, COLLIGNON P, GARDNER A. Five-year antimicrobial resistance patterns of urinary Escherichia coli at an Australian tertiary hospital: time series analyses of prevalence data. PLoS One. 2016; 11: e0164306.
TREVIÑO M, LOSADA I, FERNÁNDEZ-PÉREZ B, COIRA A, PEÑA-RODRÍGUEZ MF, HERVADA X. Surveillance of antimicrobial susceptibility of Escherichia coli producing urinary tract infections in Galicia (Spain). Rev Esp Quimioter 2016; 29: 86-90.
VAN DE SANDE-BRUINSMA N, GRUNDMANN H, VERLOO D, TIEMERSMA E, MONEN J, GOOSSENS H et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008; 14: 1722-1730.
SCHITO GC, NABER KG, BOTTO H, PALOU J, MAZZEI T, GUALCO L et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009; 34: 407-413.
BRYCE A, HAY AD, LANE IF, THORNTON HV, WOOTTON M, COSTELLOE C. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ. 2016; 352 :i939.
JUNQUERA S, LOZA E, BAQUERO F. Changes in the antimicrobial susceptibility of Escherichia coli isolates from nosocomial versus community-acquired urinary tract infections. Enferm Infecc Microbiol Clin 2005; 23:197-201.
LINHARES I, RAPOSO T, RODRIGUES A, ALMEIDA A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009). BMC Infect Dis 2013; 13: 19.
MARAKI S, MANTADAKIS E, MICHAILIDIS L, SAMONIS G. Changing antibiotic susceptibilities of community-acquired uropathogens in Greece, 2005-2010. J Microbiol Immunol Infect 2013; 46: 202-209.
NABER KG, SCHITO G, BOTTO H, PALOU J, MAZZEI T. Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy. Eur Urol 2008; 54: 1164-1175.
DREKONJA DM, JOHNSON JR. Urinary tract infections. Prim Care 2008; 35: 345-367.
AGENCIA ESPAÑOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS. Nitrofurantoina (Furantoina®): Nuevas restricciones de uso. http://www.aemps.gob.es Consultado el 10 de septiembre de 2017.
KRESKEN M, KÖRBER-IRRGANG B. In vitro activity of nitroxoline against Escherichia coli urine isolates from outpatients departments in Germany. Antimicrob Agents Chemother 2014; 58: 7019-7020.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
